PerioTrap Pharmaceuticals GmbH is thrilled to announce that it has successfully raised €2,700,000 in its latest funding round, marking a significant milestone in the company’s journey toward revolutionizing periodontal therapy. PerioTrap is at the forefront of developing an innovative anti-infective drug specifically aimed at the curative treatment of periodontitis, an inflammatory gum disease triggered by specific pathogenic bacteria. This condition affects approximately 30% of the global population and has long been managed by invasive procedures that involve manually removing plaque from dental pockets, followed by cleansing with antiseptic solutions or broad-spectrum antibiotics. Unfortunately, these traditional methods not only lead to undesirable side effects, such as the destruction of the protective biofilm and the potential development of antimicrobial resistance, but they also fail to provide a long-lasting solution to the root cause of the disease.
The freshly secured funding will accelerate PerioTrap’s efforts to bring its novel, locally applied small molecule drugs to market. These drugs are designed to target a new bacterial marker that is exclusively present in pathogenic strains while sparing beneficial commensals, thereby preserving the vital protective biofilm. An additional advantage of this technology is the local long-term release formulation, which aims to prevent pathogenic recolonization in the dental pockets—a key factor in the recurrence of periodontitis. With this innovative approach, PerioTrap envisions not only eradicating the underlying cause of periodontitis but also restoring patient confidence by offering a safer, more effective treatment alternative. This funding injection will thus play an essential role in advancing clinical trials and expediting the development process, reinforcing PerioTrap's commitment to transforming periodontal care.
